Pfizer prevails in COX-2 patent case
Executive Summary
A University of Rochester patent claiming the use of COX-2 inhibitors to treat inflammation is invalid because it failed to identify the compounds claimed, a federal appeals court says in a 1ruling for Pfizer. The university sued Pfizer in 2000, alleging that the sale of the COX-2 inhibitors Celebrex (celecoxib) and Bextra (valdecoxib) infringed the patent (2"The Pink Sheet" April 17, 2000, p. 14)...